<?xml version="1.0" encoding="utf-8"?>
<rss xmlns:itunes="http://www.itunes.com/dtds/podcast-1.0.dtd" version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
	<channel>
		<itunes:new-feed-url>http://media.peerviewpress.com/000136/podcast/pvi/xml/neurology_audio.xml</itunes:new-feed-url>
		<atom:link rel="self" href="http://podcast.peerviewpress.com/neurology/neurologychannel.xml" type="application/rss+xml" />
		<lastBuildDate>Wed, 23 Dec 2009 16:33:11 -0500</lastBuildDate>
		<title>PeerView Neurology CME/CNE/CPE Audio Podcast</title>
		<itunes:author>PVI, PeerView Institute for Medical Education</itunes:author>
		<link>http://www.peerviewpress.com</link>
		<generator>Podcast Maker v1.3.8b - http://www.lemonzdream.com/podcastmaker</generator>
		<description><![CDATA[PeerView Press is an independent, professional medical publishing company focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerView Publications, PeerView Press is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.]]></description>
		<itunes:subtitle>Thought leader perspectives on current clinical advances in medicine</itunes:subtitle>
		<itunes:summary>PeerView Press is an independent, professional medical publishing company focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerView Publications, PeerView Press is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.</itunes:summary>
		<language />
		<copyright>2006</copyright>
		<itunes:owner>
			<itunes:name>PeerView Press, 24 West 40th Street, Suite 950, New York, NY 10018</itunes:name>
			<itunes:email>webmaster@peerviewpress.com</itunes:email>
		</itunes:owner>
		<image>
			<url>http://podcast.peerviewpress.com/neurology/podcast_NeurologyCME-CNE-CPE_144.jpg</url>
			<title>PeerView Neurology CME/CNE/CPE Audio Podcast</title>
			<link>http://www.peerviewpress.com</link>
			<width>144</width>
			<height>144</height>
		</image>
		<itunes:image href="http://podcast.peerviewpress.com/neurology/podcast_NeurologyCME-CNE-CPE.jpg" />
		<category>Science &amp; Medicine</category>
		<itunes:category text="Science &amp; Medicine" />
		<itunes:keywords>CME, Medical Education, continuing medical education, CME credits, PeerView Press, inSession, inReview, CE, Neurology</itunes:keywords>
		<itunes:explicit>no</itunes:explicit>
		<item>
			<title>Michael J. Gitlin, MD - Differentiating Bipolar Disorder From Major Depressive Disorder: A Case-Based Approach to Improving Diagnosis and Treatment in Primary Care</title>
			<itunes:author>PVI, PeerView Institute for Medical Education</itunes:author>
			<description><![CDATA[Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information.]]></description>
			<itunes:subtitle>Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information.</itunes:subtitle>
			<itunes:summary>Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information.</itunes:summary>
			<enclosure type="audio/mpeg" url="http://www.podtrac.com/pts/redirect.mp3?http://podcast.peerviewpress.com/neurology/PPVNE06108p13.mp3" length="28515544" />
			<guid>http://podcast.peerviewpress.com/neurology/PPVNE06108p13.mp3</guid>
			<pubDate>Wed, 23 Dec 2009 16:17:29 -0500</pubDate>
			<category>Science, Medicine</category>
			<itunes:explicit>no</itunes:explicit>
			<itunes:duration>00:29:40</itunes:duration>
			<itunes:keywords>bipolar disorder, major depressive disorder, mood disorder, borderline personality disorder, depression</itunes:keywords>
		</item>
		<item>
			<title>CME/CNE/CPE Information - Differentiating Bipolar Disorder From Major Depressive Disorder: A Case-Based Approach to Improving Diagnosis and Treatment in Primary Care</title>
			<itunes:author>PVI, PeerView Institute for Medical Education</itunes:author>
			<description><![CDATA[Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file.]]></description>
			<itunes:subtitle>Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file.</itunes:subtitle>
			<itunes:summary>Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file.</itunes:summary>
			<enclosure type="application/pdf" url="http://podcast.peerviewpress.com/neurology/PPVNE06108CMEinfo.pdf" length="349453" />
			<guid>http://podcast.peerviewpress.com/neurology/PPVNE06108CMEinfo.pdf</guid>
			<pubDate>Wed, 23 Dec 2009 16:17:02 -0500</pubDate>
			<category>Science, Medicine</category>
			<itunes:explicit>no</itunes:explicit>
			<itunes:duration>00:00:00</itunes:duration>
			<itunes:keywords>bipolar disorder, major depressive disorder, mood disorder, borderline personality disorder, depression</itunes:keywords>
		</item>
		<item>
			<title>Timothy Vollmer, MD - Selecting Immunomodulating Therapy in Relapsing-Remitting Multiple Sclerosis</title>
			<itunes:author>PVI, PeerView Institute for Medical Education</itunes:author>
			<description><![CDATA[This 2-part, case-based activity focuses on several practical aspects of the management of relapsing-remitting multiple sclerosis. Highlights from the first case scenario include risk stratification for conversion to MS in patients who present with clinically isolated syndrome, as well as treatment selection for first-line therapy in the RRMS population. The second case study emphasizes the management of patients who are nonresponsive to first-line immunomodulating therapy. The potential role of emerging therapies for the treatment of this disease is also summarized.]]></description>
			<itunes:subtitle>Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information.</itunes:subtitle>
			<itunes:summary>This 2-part, case-based activity focuses on several practical aspects of the management of relapsing-remitting multiple sclerosis. Highlights from the first case scenario include risk stratification for conversion to MS in patients who present with clinically isolated syndrome, as well as treatment selection for first-line therapy in the RRMS population. The second case study emphasizes the management of patients who are nonresponsive to first-line immunomodulating therapy. The potential role of emerging therapies for the treatment of this disease is also summarized.</itunes:summary>
			<enclosure type="audio/mpeg" url="http://www.podtrac.com/pts/redirect.mp3?http://podcast.peerviewpress.com/neurology/PA04911FCp11.mp3" length="33081089" />
			<link>http://podcast.peerviewpress.com/neurology/PA04911FCp11.mp3</link>
			<guid>http://podcast.peerviewpress.com/neurology/PA04911FCp11.mp3</guid>
			<pubDate>Thu, 01 Oct 2009 14:33:51 -0400</pubDate>
			<category>Science, Medicine</category>
			<itunes:explicit>no</itunes:explicit>
			<itunes:duration>00:34:25</itunes:duration>
			<itunes:keywords>multiple sclerosis, MS, relapsing-remitting multiple sclerosis, RRMS, immunomodulating therapy</itunes:keywords>
		</item>
		<item>
			<title>CME/CNE/CPE Information - Selecting Immunomodulating Therapy in Relapsing-Remitting Multiple Sclerosis</title>
			<itunes:author>PVI, PeerView Institute for Medical Education</itunes:author>
			<description><![CDATA[Please view this PDF file for full CME/CNE/CPE information.  You will need Adobe Acrobat reader software to access this file.]]></description>
			<itunes:subtitle>Please view this PDF file for full CME/CNE/CPE information.  You will need Adobe Acrobat reader software to access this file.</itunes:subtitle>
			<itunes:summary>Please view this PDF file for full CME/CNE/CPE information.  You will need Adobe Acrobat reader software to access this file.</itunes:summary>
			<enclosure type="application/pdf" url="http://podcast.peerviewpress.com/neurology/PA04911FCCMEinfo.pdf" length="764903" />
			<link>http://podcast.peerviewpress.com/neurology/PA04911FCCMEinfo.pdf</link>
			<guid>http://podcast.peerviewpress.com/neurology/PA04911FCCMEinfo.pdf</guid>
			<pubDate>Thu, 01 Oct 2009 14:33:48 -0400</pubDate>
			<category>Science, Medicine</category>
			<itunes:explicit>no</itunes:explicit>
			<itunes:duration>00:00:00</itunes:duration>
			<itunes:keywords>multiple sclerosis, MS, relapsing-remitting multiple sclerosis, RRMS, immunomodulating therapy</itunes:keywords>
		</item>
		<item>
			<title>Martin R. Farlow, MD - Scientific and Clinical Frontiers in the Treatment of Alzheimer’s Disease: Identification of Novel Pathways and Development of New Treatments</title>
			<itunes:author>PVI, PeerView Institute for Medical Education</itunes:author>
			<description><![CDATA[This 2-part activity focuses on some of the pathological and clinical aspects related to regional cerebral hypometabolism in patients with Alzheimer’s disease. Part 1 includes a brief discussion of key concepts of the underlying pathophysiology of Alzheimer’s disease and a review of the aspects of cerebral hypometabolism, including genetic polymorphisms, hypothesized pathological mechanisms, and potential treatments. The second part of the activity summarizes recent clinical data related to potential treatments to improve cognitive function in Alzheimer’s disease by overcoming cerebral hypometabolism.]]></description>
			<itunes:subtitle>Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information.</itunes:subtitle>
			<itunes:summary>This 2-part activity focuses on some of the pathological and clinical aspects related to regional cerebral hypometabolism in patients with Alzheimer’s disease. Part 1 includes a brief discussion of key concepts of the underlying pathophysiology of Alzheimer’s disease and a review of the aspects of cerebral hypometabolism, including genetic polymorphisms, hypothesized pathological mechanisms, and potential treatments. The second part of the activity summarizes recent clinical data related to potential treatments to improve cognitive function in Alzheimer’s disease by overcoming cerebral hypometabolism.</itunes:summary>
			<enclosure type="audio/mpeg" url="http://www.podtrac.com/pts/redirect.mp3?http://podcast.peerviewpress.com/neurology/PPVNE05944r65.mp3" length="20672542" />
			<link>http://podcast.peerviewpress.com/neurology/PPVNE05944r65.mp3</link>
			<guid>http://podcast.peerviewpress.com/neurology/PPVNE05944r65.mp3</guid>
			<pubDate>Tue, 15 Sep 2009 14:26:36 -0400</pubDate>
			<category>Science, Medicine</category>
			<itunes:explicit>no</itunes:explicit>
			<itunes:duration>00:21:30</itunes:duration>
			<itunes:keywords>Alzheimer&apos;s; Alzheimer&apos;s disease; dementia; Alzheimer&apos;s treatments; Alzheimer&apos;s medications</itunes:keywords>
		</item>
		<item>
			<title>CME/CNE/CPE Information - Scientific and Clinical Frontiers in the Treatment of Alzheimer’s Disease: Identification of Novel Pathways and Development of New Treatments</title>
			<itunes:author>PVI, PeerView Institute for Medical Education</itunes:author>
			<description><![CDATA[Please view this PDF file for full CME/CNE/CPE information.  You will need Adobe Acrobat reader software to access this file.]]></description>
			<itunes:subtitle>Please view this PDF file for full CME/CNE/CPE information.  You will need Adobe Acrobat reader software to access this file.</itunes:subtitle>
			<itunes:summary>Please view this PDF file for full CME/CNE/CPE information.  You will need Adobe Acrobat reader software to access this file.</itunes:summary>
			<enclosure type="application/pdf" url="http://podcast.peerviewpress.com/neurology/PPVNE05944CMEinfo.pdf" length="718385" />
			<link>http://podcast.peerviewpress.com/neurology/PPVNE05944CMEinfo.pdf</link>
			<guid>http://podcast.peerviewpress.com/neurology/PPVNE05944CMEinfo.pdf</guid>
			<pubDate>Tue, 15 Sep 2009 14:26:33 -0400</pubDate>
			<category>Science, Medicine</category>
			<itunes:explicit>no</itunes:explicit>
			<itunes:duration>00:00:00</itunes:duration>
			<itunes:keywords>Alzheimer&apos;s; Alzheimer&apos;s disease; dementia; Alzheimer&apos;s treatments; Alzheimer&apos;s medications</itunes:keywords>
		</item>
		<item>
			<title>Shlomo Melmed, MD, FRCP - Improving Outcomes in Acromegaly and Cushing’s Disease: Identifying Appropriate Patients for Medical Management</title>
			<itunes:author>PVI, PeerView Institute for Medical Education</itunes:author>
			<description><![CDATA[In this activity, an expert in management of pituitary tumors discusses comorbid conditions associated with acromegaly and Cushing’s disease as well as current treatment options for pituitary tumors, focusing on pharmacotherapy.]]></description>
			<itunes:subtitle>Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information.</itunes:subtitle>
			<itunes:summary>In this activity, an expert in management of pituitary tumors discusses comorbid conditions associated with acromegaly and Cushing’s disease as well as current treatment options for pituitary tumors, focusing on pharmacotherapy.</itunes:summary>
			<enclosure type="audio/mpeg" url="http://www.podtrac.com/pts/redirect.mp3?http://podcast.peerviewpress.com/neurology/PPVNE05806n9.mp3" length="25378429" />
			<link>http://podcast.peerviewpress.com/neurology/PPVNE05806n9.mp3</link>
			<guid>http://podcast.peerviewpress.com/neurology/PPVNE05806n9.mp3</guid>
			<pubDate>Tue, 01 Sep 2009 16:37:49 -0400</pubDate>
			<category>Science, Medicine</category>
			<itunes:explicit>no</itunes:explicit>
			<itunes:duration>00:26:23</itunes:duration>
			<itunes:keywords>acromegaly, Cushing&apos;s disease, pituitary tumor, growth hormone, hypercortisolism, somatostatin receptor ligands, pasireotide, surgery</itunes:keywords>
		</item>
		<item>
			<title>CME/CNE/CPE - Improving Outcomes in Acromegaly and Cushing’s Disease: Identifying Appropriate Patients for Medical Management</title>
			<itunes:author>PVI, PeerView Institute for Medical Education</itunes:author>
			<description><![CDATA[Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat software to access this file.]]></description>
			<itunes:subtitle>Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat software to access this file.</itunes:subtitle>
			<itunes:summary>Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat software to access this file.</itunes:summary>
			<enclosure type="application/pdf" url="http://podcast.peerviewpress.com/neurology/PPVNE05806CMEinfo.pdf" length="731403" />
			<link>http://podcast.peerviewpress.com/neurology/PPVNE05806CMEinfo.pdf</link>
			<guid>http://podcast.peerviewpress.com/neurology/PPVNE05806CMEinfo.pdf</guid>
			<pubDate>Tue, 01 Sep 2009 16:37:07 -0400</pubDate>
			<category>Science, Medicine</category>
			<itunes:explicit>no</itunes:explicit>
			<itunes:duration>00:00:00</itunes:duration>
			<itunes:keywords>acromegaly, Cushing&apos;s disease, pituitary tumor, growth hormone, hypercortisolism, somatostatin receptor ligands, pasireotide, surgery</itunes:keywords>
		</item>
		<item>
			<title>Henry S. Friedman, MD - Assessing the Safety and Efficacy of Emerging Therapies in Newly Diagnosed and Recurring Glioblastoma Multiforme: Latest Results From Orlando</title>
			<itunes:author>PVI, PeerView Institute for Medical Education</itunes:author>
			<description><![CDATA[In this activity, experts discuss the latest clinical trial data on targeted and other new therapies for glioblastoma multiforme, assess the clinical implications of these data, and review some of the key ongoing studies that clinicians and patients should be aware of.]]></description>
			<itunes:subtitle>Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information.</itunes:subtitle>
			<itunes:summary>In this activity, experts discuss the latest clinical trial data on targeted and other new therapies for glioblastoma multiforme, assess the clinical implications of these data, and review some of the key ongoing studies that clinicians and patients should be aware of.</itunes:summary>
			<enclosure type="audio/mpeg" url="http://www.podtrac.com/pts/redirect.mp3?http://podcast.peerviewpress.com/neurology/PPVNE05931s554.mp3" length="16950006" />
			<link>http://podcast.peerviewpress.com/neurology/PPVNE05931s554.mp3</link>
			<guid>http://podcast.peerviewpress.com/neurology/PPVNE05931s554.mp3</guid>
			<pubDate>Fri, 24 Jul 2009 14:45:54 -0400</pubDate>
			<category>Science, Medicine</category>
			<itunes:explicit>no</itunes:explicit>
			<itunes:duration>00:17:37</itunes:duration>
			<itunes:keywords>glioblastoma multiforme, GBM, bevacizumab, temozolomide, radiation, VEGF inhibitor, mTOR, irinotecan, antiangiogenic, immunostimulation </itunes:keywords>
		</item>
		<item>
			<title>CME/CNE/CPE Information - Assessing the Safety and Efficacy of Emerging Therapies in Newly Diagnosed and Recurring Glioblastoma Multiforme: Latest Results From Orlando</title>
			<itunes:author>PVI, PeerView Institute for Medical Education</itunes:author>
			<description><![CDATA[Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file.]]></description>
			<itunes:subtitle>Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file.</itunes:subtitle>
			<itunes:summary>Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file.</itunes:summary>
			<enclosure type="application/pdf" url="http://podcast.peerviewpress.com/neurology/PPVNE05931CMEinfo.pdf" length="257648" />
			<link>http://podcast.peerviewpress.com/neurology/PPVNE05931CMEinfo.pdf</link>
			<guid>http://podcast.peerviewpress.com/neurology/PPVNE05931CMEinfo.pdf</guid>
			<pubDate>Fri, 24 Jul 2009 14:45:35 -0400</pubDate>
			<category>Science, Medicine</category>
			<itunes:explicit>no</itunes:explicit>
			<itunes:duration>00:00:00</itunes:duration>
			<itunes:keywords>glioblastoma multiforme, GBM, bevacizumab, temozolomide, radiation, VEGF inhibitor, mTOR, irinotecan, antiangiogenic, immunostimulation </itunes:keywords>
		</item>
		<item>
			<title>Stuart J. Connolly, MD, FRCPC - The Evolving Role of Antiplatelet Therapy for Atrial Fibrillation: Highlights From the ACC Scientific Sessions 2009</title>
			<itunes:author>PVI, PeerView Institute for Medical Education</itunes:author>
			<description><![CDATA[In this activity, experts in management of stroke prevention in patients with atrial fibrillation discuss challenges and controversies with the current standard of care for stroke prevention and analyze emerging options for stroke prevention.]]></description>
			<itunes:subtitle>Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information.</itunes:subtitle>
			<itunes:summary>In this activity, experts in management of stroke prevention in patients with atrial fibrillation discuss challenges and controversies with the current standard of care for stroke prevention and analyze emerging options for stroke prevention.</itunes:summary>
			<enclosure type="audio/mpeg" url="http://www.podtrac.com/pts/redirect.mp3?http://podcast.peerviewpress.com/neurology/PI04851FC_s551.mp3" length="26950263" />
			<link>http://podcast.peerviewpress.com/neurology/PI04851FC_s551.mp3</link>
			<guid>http://podcast.peerviewpress.com/neurology/PI04851FC_s551.mp3</guid>
			<pubDate>Tue, 16 Jun 2009 14:16:43 -0400</pubDate>
			<category>Science, Medicine</category>
			<itunes:explicit>no</itunes:explicit>
			<itunes:duration>00:28:02</itunes:duration>
			<itunes:keywords>atrial fibrillation, stroke, stroke prevention, antiplatelet therapy, anticoagulation, vitamin K antagonists</itunes:keywords>
		</item>
		<item>
			<title>CME/CNE/CPE Information - The Evolving Role of Antiplatelet Therapy for Atrial Fibrillation: Highlights From the ACC Scientific Sessions 2009</title>
			<itunes:author>PVI, PeerView Institute for Medical Education</itunes:author>
			<description><![CDATA[Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat software to access this file.]]></description>
			<itunes:subtitle>Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat software to access this file.</itunes:subtitle>
			<itunes:summary>Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat software to access this file.</itunes:summary>
			<enclosure type="application/pdf" url="http://podcast.peerviewpress.com/neurology/PI04851FCCMEinfo.pdf" length="312849" />
			<link>http://podcast.peerviewpress.com/neurology/PI04851FCCMEinfo.pdf</link>
			<guid>http://podcast.peerviewpress.com/neurology/PI04851FCCMEinfo.pdf</guid>
			<pubDate>Tue, 16 Jun 2009 14:16:41 -0400</pubDate>
			<category>Science, Medicine</category>
			<itunes:explicit>no</itunes:explicit>
			<itunes:duration>00:00:00</itunes:duration>
			<itunes:keywords>atrial fibrillation, stroke, stroke prevention, antiplatelet therapy, anticoagulation, vitamin K antagonists</itunes:keywords>
		</item>
		<item>
			<title>Jerome Engel, Jr., MD, PhD - Improving Epilepsy Management Throughout the Disease Continuum</title>
			<itunes:author>PVI, PeerView Institute for Medical Education</itunes:author>
			<description><![CDATA[In this activity, an expert in epilepsy management discusses epilepsy diagnosis, treatment, and considerations for special populations with epilepsy.]]></description>
			<itunes:subtitle>Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information.</itunes:subtitle>
			<itunes:summary>In this activity, an expert in epilepsy management discusses epilepsy diagnosis, treatment, and considerations for special populations with epilepsy.</itunes:summary>
			<enclosure type="audio/mpeg" url="http://www.podtrac.com/pts/redirect.mp3?http://podcast.peerviewpress.com/neurology/PA05075FCn195.mp3" length="39728716" />
			<link>http://podcast.peerviewpress.com/neurology/PA05075FCn195.mp3</link>
			<guid>http://podcast.peerviewpress.com/neurology/PA05075FCn195.mp3</guid>
			<pubDate>Mon, 04 May 2009 11:51:40 -0400</pubDate>
			<category>Science</category>
			<itunes:explicit>no</itunes:explicit>
			<itunes:duration>00:41:21</itunes:duration>
			<itunes:keywords>epilepsy, epileptic seizures, paroxysmal events, antiepileptic drugs, surgery, ILAE, teratogenicity</itunes:keywords>
		</item>
		<item>
			<title>CME/CNE/CPE Information - Improving Epilepsy Management Throughout the Disease Continuum </title>
			<itunes:author>PVI, PeerView Institute for Medical Education</itunes:author>
			<description><![CDATA[Please view this PDF file for full CME/CNE/CPE information.  You will need Adobe Acrobat reader software to access this file.]]></description>
			<itunes:subtitle>Please view this PDF file for full CME/CNE/CPE information.  You will need Adobe Acrobat reader software to access this file.</itunes:subtitle>
			<itunes:summary>Please view this PDF file for full CME/CNE/CPE information.  You will need Adobe Acrobat reader software to access this file.</itunes:summary>
			<enclosure type="application/pdf" url="http://podcast.peerviewpress.com/neurology/PA05075FCCMEinfo.pdf" length="942852" />
			<link>http://podcast.peerviewpress.com/neurology/PA05075FCCMEinfo.pdf</link>
			<guid>http://podcast.peerviewpress.com/neurology/PA05075FCCMEinfo.pdf</guid>
			<pubDate>Mon, 04 May 2009 11:51:38 -0400</pubDate>
			<category>Science</category>
			<itunes:explicit>no</itunes:explicit>
			<itunes:duration>00:00:00</itunes:duration>
			<itunes:keywords>epilepsy, epileptic seizures, paroxysmal events, antiepileptic drugs, surgery, ILAE, teratogenicity</itunes:keywords>
		</item>
		<item>
			<title>Scott H. Kollins, PhD, MS - Insights on Adult ADHD: Recognition, Diagnosis, and Treatment</title>
			<itunes:author>PVI, PeerView Institute for Medical Education</itunes:author>
			<description><![CDATA[In this activity, experts in the management of adult ADHD discuss the challenges in diagnosing and treating ADHD in adults.]]></description>
			<itunes:subtitle>Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information.</itunes:subtitle>
			<itunes:summary>In this activity, experts in the management of adult ADHD discuss the challenges in diagnosing and treating ADHD in adults.</itunes:summary>
			<enclosure type="audio/mpeg" url="http://www.podtrac.com/pts/redirect.mp3?http://podcast.peerviewpress.com/neurology/PA03852FCr421.mp3" length="44559485" />
			<link>http://podcast.peerviewpress.com/neurology/PA03852FCr421.mp3</link>
			<guid>http://podcast.peerviewpress.com/neurology/PA03852FCr421.mp3</guid>
			<pubDate>Fri, 20 Mar 2009 15:07:25 -0400</pubDate>
			<category>Science, Medicine</category>
			<itunes:explicit>no</itunes:explicit>
			<itunes:duration>00:46:23</itunes:duration>
			<itunes:keywords>Attention-deficit/hyperactivity disorder, ADHD, impulsivity, hyperactivity, anxiety, depression, substance abuse, stimulant therapy, nonstimulant therapy, cognitive-behavioral therapy</itunes:keywords>
		</item>
		<item>
			<title>CME/CNE/CPE Information - Insights on Adult ADHD: Recognition, Diagnosis, and Treatment</title>
			<itunes:author>PVI, PeerView Institute for Medical Education</itunes:author>
			<description><![CDATA[Please view this PDF file for full CME/CNE/CPE information.  You will need Adobe Acrobat reader software to access this file.]]></description>
			<itunes:subtitle>Please view this PDF file for full CME/CNE/CPE information.  You will need Adobe Acrobat reader software to access this file.</itunes:subtitle>
			<itunes:summary>Please view this PDF file for full CME/CNE/CPE information.  You will need Adobe Acrobat reader software to access this file.</itunes:summary>
			<enclosure type="application/pdf" url="http://podcast.peerviewpress.com/neurology/PA03852FCCMEinfo.pdf" length="643851" />
			<link>http://podcast.peerviewpress.com/neurology/PA03852FCCMEinfo.pdf</link>
			<guid>http://podcast.peerviewpress.com/neurology/PA03852FCCMEinfo.pdf</guid>
			<pubDate>Fri, 20 Mar 2009 15:07:11 -0400</pubDate>
			<category>Science, Medicine</category>
			<itunes:explicit>no</itunes:explicit>
			<itunes:duration>00:00:00</itunes:duration>
			<itunes:keywords>Attention-deficit/hyperactivity disorder, ADHD, impulsivity, hyperactivity, anxiety, depression, substance abuse, stimulant therapy, nonstimulant therapy, cognitive-behavioral therapy</itunes:keywords>
		</item>
		<item>
			<title>Brett R. Stacey, MD - A Case-Based Approach to Recognizing and Managing Diabetic Peripheral Neuropathy</title>
			<itunes:author>PVI, PeerView Institute for Medical Education</itunes:author>
			<description><![CDATA[In this activity, an expert in painful DPN discusses differential diagnosis of the condition and management approaches in treatment-naïve patients as well as in individuals with established diagnosis.]]></description>
			<itunes:subtitle>Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information.</itunes:subtitle>
			<itunes:summary>In this activity, an expert in painful DPN discusses differential diagnosis of the condition and management approaches in treatment-naïve patients as well as in individuals with established diagnosis.</itunes:summary>
			<enclosure type="audio/mpeg" url="http://www.podtrac.com/pts/redirect.mp3?http://podcast.peerviewpress.com/neurology/PA05052FCp151.mp3" length="26578071" />
			<link>http://podcast.peerviewpress.com/neurology/PA05052FCp151.mp3</link>
			<guid>http://podcast.peerviewpress.com/neurology/PA05052FCp151.mp3</guid>
			<pubDate>Mon, 09 Mar 2009 14:03:52 -0400</pubDate>
			<category>Science, Medicine</category>
			<itunes:explicit>no</itunes:explicit>
			<itunes:duration>00:27:39</itunes:duration>
			<itunes:keywords>diabetic peripheral neuropathy, DPN, diabetes, neuropathic pain, nerve damage, pregabalin, duloxetine, diagnosis</itunes:keywords>
		</item>
		<item>
			<title>CME/CNE/CPE Information - A Case-Based Approach to Recognizing and Managing Diabetic Peripheral Neuropathy</title>
			<itunes:author>PeerView Press</itunes:author>
			<description><![CDATA[Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat software to access this file.]]></description>
			<itunes:subtitle>Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat software to access this file.</itunes:subtitle>
			<itunes:summary>Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat software to access this file.</itunes:summary>
			<enclosure type="application/pdf" url="http://podcast.peerviewpress.com/neurology/PA05052FCCMEinfo.pdf" length="705388" />
			<link>http://podcast.peerviewpress.com/neurology/PA05052FCCMEinfo.pdf</link>
			<guid>http://podcast.peerviewpress.com/neurology/PA05052FCCMEinfo.pdf</guid>
			<pubDate>Mon, 09 Mar 2009 14:03:48 -0400</pubDate>
			<category>Science, Medicine</category>
			<itunes:explicit>no</itunes:explicit>
			<itunes:duration>00:00:00</itunes:duration>
			<itunes:keywords>diabetic peripheral neuropathy, DPN, diabetes, neuropathic pain, nerve damage, pregabalin, duloxetine, diagnosis</itunes:keywords>
		</item>
		<item>
			<title>I. Jon Russell, MD, PhD - Uncovering the Complexities of Fibromyalgia Syndrome and Simplifying Its Management</title>
			<itunes:author>PVI, PeerView Institute for Medical Education</itunes:author>
			<description><![CDATA[In this activity, Dr. I. Jon Russell, MD, PhD, an expert in the field of fibromyalgia syndrome (FMS), will explore current evidence on the etiology and pathophysiology of the disorder. He will also provide an overview of pharmacologic options available to treat symptoms of FMS as well as accompanying conditions. Multidimensional approaches to management of FMS consisting of strategic polypharmacy, nonpharmacologic interventions, as well as multidisciplinary care will also be profiled in this activity.]]></description>
			<itunes:subtitle>Please be sure to view the accompanying (PDF) file for full CME information.</itunes:subtitle>
			<itunes:summary>In this activity, Dr. I. Jon Russell, MD, PhD, an expert in the field of fibromyalgia syndrome (FMS), will explore current evidence on the etiology and pathophysiology of the disorder. He will also provide an overview of pharmacologic options available to treat symptoms of FMS as well as accompanying conditions. Multidimensional approaches to management of FMS consisting of strategic polypharmacy, nonpharmacologic interventions, as well as multidisciplinary care will also be profiled in this activity.</itunes:summary>
			<enclosure type="audio/mpeg" url="http://www.podtrac.com/pts/redirect.mp3?http://podcast.peerviewpress.com/neurology/PA05055FCn204.mp3" length="32234807" />
			<link>http://podcast.peerviewpress.com/neurology/PA05055FCn204.mp3</link>
			<guid>http://podcast.peerviewpress.com/neurology/PA05055FCn204.mp3</guid>
			<pubDate>Tue, 20 Jan 2009 10:56:55 -0500</pubDate>
			<category>Science</category>
			<itunes:explicit>no</itunes:explicit>
			<itunes:duration>00:33:32</itunes:duration>
			<itunes:keywords>fibromyalgia syndrome, pain, stiffness, fatigue, antidepressants, brain trauma, febrile illness, genetic predisposition, allodynia, pregabalin</itunes:keywords>
		</item>
		<item>
			<title>CME Information - Uncovering the Complexities of Fibromyalgia Syndrome and Simplifying Its Management</title>
			<itunes:author>PVI, PeerView Institute for Medical Education</itunes:author>
			<description><![CDATA[Please view this PDF file for full CME information.  You will need Adobe Acrobat reader software to access this file.]]></description>
			<itunes:subtitle>Please view this PDF file for full CME information.  You will need Adobe Acrobat reader software to access this file.</itunes:subtitle>
			<itunes:summary>Please view this PDF file for full CME information.  You will need Adobe Acrobat reader software to access this file.</itunes:summary>
			<enclosure type="application/pdf" url="http://podcast.peerviewpress.com/neurology/PA05055FCCMEinformation.pdf" length="714531" />
			<link>http://podcast.peerviewpress.com/neurology/PA05055FCCMEinfo.pdf</link>
			<guid>http://podcast.peerviewpress.com/neurology/PA05055FCCMEinformation.pdf</guid>
			<pubDate>Tue, 20 Jan 2009 10:55:55 -0500</pubDate>
			<category>Science</category>
			<itunes:explicit>no</itunes:explicit>
			<itunes:duration>00:00:00</itunes:duration>
			<itunes:keywords>fibromyalgia syndrome, pain, stiffness, fatigue, antidepressants, brain trauma, febrile illness, genetic predisposition, allodynia, pregabalin</itunes:keywords>
		</item>
		<item>
			<title>David Geldmacher, MD - Advances in Alzheimer&apos;s Disease and Vascular Dementia: Benchmarks in Diagnosis and Treatment</title>
			<itunes:author>PVI, PeerView Institute for Medical Education</itunes:author>
			<description><![CDATA[In this CME/CE activity, experts in the management of dementia present recent data on the diagnosis and treatment of Alzheimer's disease and vascular dementia.]]></description>
			<itunes:subtitle>Please be sure to view the accompanying (PDF) file for full CME/CE information.</itunes:subtitle>
			<itunes:summary>In this CME/CE activity, experts in the management of dementia present recent data on the diagnosis and treatment of Alzheimer&apos;s disease and vascular dementia.</itunes:summary>
			<enclosure type="application/pdf" url="http://podcast.peerviewpress.com/neurology/PA04467FCCMEinfo.pdf" length="317890" />
			<link>http://podcast.peerviewpress.com/neurology/PA04467FCr379.mp3</link>
			<guid>http://podcast.peerviewpress.com/neurology/PA04467FCCMEinfo.pdf</guid>
			<pubDate>Wed, 06 Aug 2008 14:56:47 -0400</pubDate>
			<category>Science</category>
			<itunes:explicit>no</itunes:explicit>
			<itunes:duration>00:00:00</itunes:duration>
			<itunes:keywords>memantine, rivastigmine, galantamine, donepezil, cholinesterase inhibitors, NMDA-receptor antagonist, Alzheimer&apos;s disease, vascular dementia, mild cognitive impairment, MRI</itunes:keywords>
		</item>
		<item>
			<title>CME/CE Information - Advances in Alzheimer&apos;s Disease and Vascular Dementia: Benchmarks in Diagnosis and Treatment</title>
			<itunes:author>PVI, PeerView Institute for Medical Education</itunes:author>
			<description><![CDATA[Please view this PDF file for full CME/CE information.  You will need Adobe Acrobat reader software to access this file.]]></description>
			<itunes:subtitle>Please view this PDF file for full CME/CE information.  You will need Adobe Acrobat reader software to access this file.</itunes:subtitle>
			<itunes:summary>Please view this PDF file for full CME/CE information.  You will need Adobe Acrobat reader software to access this file.</itunes:summary>
			<enclosure type="audio/mpeg" url="http://www.podtrac.com/pts/redirect.mp3?http://podcast.peerviewpress.com/neurology/PA04467FCr379.mp3" length="56345912" />
			<link>http://podcast.peerviewpress.com/neurology/PA04467FCCMEinfo.pdf</link>
			<guid>http://podcast.peerviewpress.com/neurology/PA04467FCr379.mp3</guid>
			<pubDate>Wed, 06 Aug 2008 14:54:47 -0400</pubDate>
			<category>Science</category>
			<itunes:explicit>no</itunes:explicit>
			<itunes:duration>00:58:37</itunes:duration>
			<itunes:keywords>memantine, rivastigmine, galantamine, donepezil, cholinesterase inhibitors, NMDA-receptor antagonist, Alzheimer&apos;s disease, vascular dementia, mild cognitive impairment, MRI</itunes:keywords>
		</item>
		<item>
			<title>Robert M. Bennett, MD - Optimal Management of Fibromyalgia: A Multidisciplinary Roundtable Discussion</title>
			<itunes:author>PVI, PeerView Institute for Medical Education</itunes:author>
			<description><![CDATA[In this CME/CE activity, experts in the management of FMS discuss diagnosis and management of this complex disorder. Strategies for collaboration between multiple specialties in the treatment of patients with FMS are also highlighted.]]></description>
			<itunes:subtitle>Please be sure to view the accompanying (PDF) file for full CME/CE information.</itunes:subtitle>
			<itunes:summary>In this CME/CE activity, experts in the management of FMS discuss diagnosis and management of this complex disorder. Strategies for collaboration between multiple specialties in the treatment of patients with FMS are also highlighted.</itunes:summary>
			<enclosure type="audio/mpeg" url="http://www.podtrac.com/pts/redirect.mp3?http://podcast.peerviewpress.com/neurology/PA04412FCe016.mp3" length="63286082" />
			<link>http://podcast.peerviewpress.com/neurology/PA04412FCe016.mp3</link>
			<guid>http://podcast.peerviewpress.com/neurology/PA04412FCe016.mp3</guid>
			<pubDate>Fri, 18 Jul 2008 10:40:08 -0400</pubDate>
			<category>Science</category>
			<itunes:explicit>no</itunes:explicit>
			<itunes:duration>01:05:51</itunes:duration>
			<itunes:keywords>Tender points, duloxetine, pregabalin, gabapentin, milnacipran, pramipexole, exercise, pain, cognitive-behavioral therapy, EULAR, ACR, depression, sleep</itunes:keywords>
		</item>
		<item>
			<title>CME/CE Information - Optimal Management of Fibromyalgia: A Multidisciplinary Roundtable Discussion</title>
			<itunes:author>PVI, PeerView Institute for Medical Education</itunes:author>
			<description><![CDATA[Please view this PDF file for full CME/CE information.  You will need Adobe Acrobat reader software to access this file.]]></description>
			<itunes:subtitle>Please view this PDF file for full CME/CE information.  You will need Adobe Acrobat reader software to access this file.</itunes:subtitle>
			<itunes:summary>Please view this PDF file for full CME/CE information.  You will need Adobe Acrobat reader software to access this file.</itunes:summary>
			<enclosure type="application/pdf" url="http://podcast.peerviewpress.com/neurology/PA04412FCCMEinfo.pdf" length="260181" />
			<link>http://podcast.peerviewpress.com/neurology/PA04421FCCMEinfo.pdf</link>
			<guid>http://podcast.peerviewpress.com/neurology/PA04412FCCMEinfo.pdf</guid>
			<pubDate>Fri, 18 Jul 2008 10:39:08 -0400</pubDate>
			<category>Science</category>
			<itunes:explicit>no</itunes:explicit>
			<itunes:duration>00:00:00</itunes:duration>
			<itunes:keywords>Tender points, duloxetine, pregabalin, gabapentin, milnacipran, pramipexole, exercise, pain, cognitive-behavioral therapy, EULAR, ACR, depression, sleep</itunes:keywords>
		</item>
		<item>
			<title>Patricia K. Coyle, MD - Concepts in the Treatment of MS: New Data on Standard Approaches and Future Possibilities</title>
			<itunes:author>PVI, PeerView Institute for Medical Education</itunes:author>
			<description><![CDATA[In this CME activity, experts in the treatment of multiple sclerosis consider recent studies on the early treatment of MS.  Long-term data on safety and efficacy and head-to-head comparisons of available therapies are presented.]]></description>
			<itunes:subtitle>Please be sure to view the accompanying (PDF) file for full CME/CE information.</itunes:subtitle>
			<itunes:summary>In this CME activity, experts in the treatment of multiple sclerosis consider recent studies on the early treatment of MS.  Long-term data on safety and efficacy and head-to-head comparisons of available therapies are presented.</itunes:summary>
			<enclosure type="audio/mpeg" url="http://www.podtrac.com/pts/redirect.mp3?http://podcast.peerviewpress.com/neurology/PA04011FCr378.mp3" length="28742216" />
			<link>http://podcast.peerviewpress.com/neurology/PA04011FCr378.mp3</link>
			<guid>http://podcast.peerviewpress.com/neurology/PA04011FCr378.mp3</guid>
			<pubDate>Thu, 03 Jul 2008 09:25:25 -0400</pubDate>
			<category>Science</category>
			<itunes:explicit>no</itunes:explicit>
			<itunes:duration>00:29:52</itunes:duration>
			<itunes:keywords>MS, interferon, glatiramer acetate, mitoxantrone, natalizumab, PRISMS, CHAMPS, CHAMPIONS, ETOMS, REFLEX, BENEFIT, PRECISE</itunes:keywords>
		</item>
		<item>
			<title>CME/CE Information - Concepts in the Treatment of MS: New Data on Standard Approaches and Future Possibilities</title>
			<itunes:author>PVI, PeerView Institute for Medical Education</itunes:author>
			<description><![CDATA[Please view this PDF file for full CME/CE information.  You will need Adobe Acrobat reader software to access this file.]]></description>
			<itunes:subtitle>Please view this PDF file for full CME/CE information.  You will need Adobe Acrobat reader software to access this file.</itunes:subtitle>
			<itunes:summary>Please view this PDF file for full CME/CE information.  You will need Adobe Acrobat reader software to access this file.</itunes:summary>
			<enclosure type="application/pdf" url="http://podcast.peerviewpress.com/neurology/PA04011FCCMEinfo.pdf" length="253543" />
			<link>http://podcast.peerviewpress.com/neurology/PA04011FCCMEinfo.pdf</link>
			<guid>http://podcast.peerviewpress.com/neurology/PA04011FCCMEinfo.pdf</guid>
			<pubDate>Thu, 03 Jul 2008 09:25:22 -0400</pubDate>
			<category>Science</category>
			<itunes:explicit>no</itunes:explicit>
			<itunes:duration>00:00:00</itunes:duration>
			<itunes:keywords>MS, interferon, glatiramer acetate, mitoxantrone, natalizumab, PRISMS, CHAMPS, CHAMPIONS, ETOMS, REFLEX, BENEFIT, PRECISE</itunes:keywords>
		</item>
		<item>
			<title>Emmanuelle L. Waubant, MD, PhD - Recognizing and Anticipating Therapy-Related Adverse Events in Multiple Sclerosis</title>
			<itunes:author>PVI, PeerView Institute for Medical Education</itunes:author>
			<description><![CDATA[In this activity, experts in the treatment of multiple sclerosis present the most current safety data associated with the use of broad-spectrum immunomodulatory/immunosuppressive agents and monoclonal antibodies in multiple sclerosis. In addition, the investigational status of oral therapies in MS is clarified.]]></description>
			<itunes:subtitle>Please be sure to view the accompanying (PDF) file for full CME/CE information.</itunes:subtitle>
			<itunes:summary>In this activity, experts in the treatment of multiple sclerosis present the most current safety data associated with the use of broad-spectrum immunomodulatory/immunosuppressive agents and monoclonal antibodies in multiple sclerosis. In addition, the investigational status of oral therapies in MS is clarified.</itunes:summary>
			<enclosure type="audio/mpeg" url="http://www.podtrac.com/pts/redirect.mp3?http://podcast.peerviewpress.com/neurology/PA04137FCr359.mp3" length="37036239" />
			<link>http://podcast.peerviewpress.com/neurology/PA04137FCr359.mp3</link>
			<guid>http://podcast.peerviewpress.com/neurology/PA04137FCr359.mp3</guid>
			<pubDate>Thu, 24 Jan 2008 11:44:01 -0500</pubDate>
			<category>Science</category>
			<itunes:explicit>no</itunes:explicit>
			<itunes:duration>00:30:48</itunes:duration>
			<itunes:keywords>Multiple sclerosis, Interferon beta, Glatiramer acetate, Mitoxantrone, Cyclophosphamide, Azathioprine, Mycophenolate mofetil, Natalizumab, Rituximab, Daclizumab, Alemtuzumab, Cladribine, Fingolimod, Teriflunomide, Laquinimod, BG-12, Dimethyl fumarate</itunes:keywords>
		</item>
		<item>
			<title>CME/CE Information - Recognizing and Anticipating Therapy-Related Adverse Events in Multiple Sclerosis</title>
			<itunes:author>PVI, PeerView Institute for Medical Education</itunes:author>
			<description><![CDATA[Please view this PDF file for full CME/CE information.  You will need Adobe Acrobat reader software to access this file.]]></description>
			<itunes:subtitle>Please view this PDF file for full CME/CE information.  You will need Adobe Acrobat reader software to access this file.</itunes:subtitle>
			<itunes:summary>Please view this PDF file for full CME/CE information.  You will need Adobe Acrobat reader software to access this file.</itunes:summary>
			<enclosure type="application/pdf" url="http://podcast.peerviewpress.com/neurology/PA04137FCCMEinfo.pdf" length="239464" />
			<link>http://podcast.peerviewpress.com/neurology/PA04137FCCMEinfo.pdf</link>
			<guid>http://podcast.peerviewpress.com/neurology/PA04137FCCMEinfo.pdf</guid>
			<pubDate>Thu, 24 Jan 2008 11:43:01 -0500</pubDate>
			<category>Science</category>
			<itunes:explicit>no</itunes:explicit>
			<itunes:duration>00:00:00</itunes:duration>
			<itunes:keywords>Multiple sclerosis, Interferon beta, Glatiramer acetate, Mitoxantrone, Cyclophosphamide, Azathioprine, Mycophenolate mofetil, Natalizumab, Rituximab, Daclizumab, Alemtuzumab, Cladribine, Fingolimod, Teriflunomide, Laquinimod, BG-12, Dimethyl fumarate</itunes:keywords>
		</item>
		<item>
			<title>Amit Bar-Or, MD, FRCP - Data Updates for Monoclonal Antibodies in Multiple Sclerosis</title>
			<itunes:author>PVI, PeerView Institute for Medical Education</itunes:author>
			<description><![CDATA[In this activity, experts in the treatment of multiple sclerosis discuss data presented at the 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2007) concerning the use of the monoclonal antibodies natalizumab, rituximab, daclizumab, and alemtuzumab in this disorder. ]]></description>
			<itunes:subtitle>Please be sure to view the accompanying (PDF) file for full CME/CE information.</itunes:subtitle>
			<itunes:summary>In this activity, experts in the treatment of multiple sclerosis discuss data presented at the 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2007) concerning the use of the monoclonal antibodies natalizumab, rituximab, daclizumab, and alemtuzumab in this disorder. </itunes:summary>
			<enclosure type="audio/mpeg" url="http://www.podtrac.com/pts/redirect.mp3?http://podcast.peerviewpress.com/neurology/PA03646FC3s430.mp3" length="25015152" />
			<link>http://podcast.peerviewpress.com/neurology/PA03646FC3s430.mp3</link>
			<guid>http://podcast.peerviewpress.com/neurology/PA03646FC3s430.mp3</guid>
			<pubDate>Fri, 11 Jan 2008 17:31:01 -0500</pubDate>
			<category>Science</category>
			<itunes:explicit>no</itunes:explicit>
			<itunes:duration>00:25:58</itunes:duration>
			<itunes:keywords>Multiple sclerosis,Alemtuzumab,Natalizumab,Rituximab,Daclizumab,Monoclonal antibody,T cell,B cell,Epstein-Barr virus (EBV), Neuromyelitis optica,European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)</itunes:keywords>
		</item>
		<item>
			<title>CME/CE Information - Data Updates for Monoclonal Antibodies in Multiple Sclerosis</title>
			<itunes:author>PVI, PeerView Institute for Medical Education</itunes:author>
			<description><![CDATA[Please view this PDF file for full CME/CE information.  You will need Adobe Acrobat reader software to access this file.]]></description>
			<itunes:subtitle>Please view this PDF file for full CME/CE information.  You will need Adobe Acrobat reader software to access this file.</itunes:subtitle>
			<itunes:summary>Please view this PDF file for full CME/CE information.  You will need Adobe Acrobat reader software to access this file.</itunes:summary>
			<enclosure type="application/pdf" url="http://podcast.peerviewpress.com/neurology/PA03646FC3CMEinfo.pdf" length="224314" />
			<link>http://podcast.peerviewpress.com/neurology/PA03646FC3CMEinfo.pdf</link>
			<guid>http://podcast.peerviewpress.com/neurology/PA03646FC3CMEinfo.pdf</guid>
			<pubDate>Fri, 11 Jan 2008 17:30:57 -0500</pubDate>
			<category>Science</category>
			<itunes:explicit>no</itunes:explicit>
			<itunes:duration>00:00:00</itunes:duration>
			<itunes:keywords>CME, Medical Education, continuing medical education, CME credits, PeerView Press, inSession, inReview, CE, Neurology</itunes:keywords>
		</item>
		<item>
			<title> R. Philip Kinkel, MD - Emerging Options in the Management of Multiple Sclerosis</title>
			<itunes:author>PVI, PeerView Institute for Medical Education</itunes:author>
			<description><![CDATA[ In this activity, an expert in the management of multiple sclerosis (MS) discusses data supporting the early use of interferon-beta and describes the current clinical development of targeted agents and oral compounds in this condition.]]></description>
			<itunes:subtitle>Please be sure to view the accompanying (PDF) file for full CME/CE information.</itunes:subtitle>
			<itunes:summary> In this activity, an expert in the management of multiple sclerosis (MS) discusses data supporting the early use of interferon-beta and describes the current clinical development of targeted agents and oral compounds in this condition.</itunes:summary>
			<enclosure type="audio/mpeg" url="http://www.podtrac.com/pts/redirect.mp3?http://podcast.peerviewpress.com/neurology/PA03748FCn168.mp3" length="21663282" />
			<link>http://podcast.peerviewpress.com/neurology/PA03748FCn168.mp3</link>
			<guid>http://podcast.peerviewpress.com/neurology/PA03748FCn168.mp3</guid>
			<pubDate>Wed, 14 Nov 2007 15:50:49 -0500</pubDate>
			<category>Science</category>
			<itunes:explicit>no</itunes:explicit>
			<itunes:duration>00:22:29</itunes:duration>
			<itunes:keywords>Multiple sclerosis, Interferon-beta, Glatiramer acetate, Natalizumab, Rituximab, Daclizumab, Alemtuzumab, Cladribine, Fingolimod, Teriflunomide, Laquinimod, BG00012</itunes:keywords>
		</item>
		<item>
			<title>CME/CE Information - Emerging Options in the Management of Multiple Sclerosis</title>
			<itunes:author>PVI, PeerView Institute for Medical Education</itunes:author>
			<description><![CDATA[Please view this PDF file for full CME/CE information.  You will need Adobe Acrobat reader software to access this file.]]></description>
			<itunes:subtitle>Please view this PDF file for full CME/CE information.  You will need Adobe Acrobat reader software to access this file.</itunes:subtitle>
			<itunes:summary>Please view this PDF file for full CME/CE information.  You will need Adobe Acrobat reader software to access this file.</itunes:summary>
			<enclosure type="application/pdf" url="http://podcast.peerviewpress.com/neurology/PA03748FCCMEinfo.pdf" length="239596" />
			<link>http://podcast.peerviewpress.com/neurology/PA03748FCCMEinfo.pdf</link>
			<guid>http://podcast.peerviewpress.com/neurology/PA03748FCCMEinfo.pdf</guid>
			<pubDate>Wed, 14 Nov 2007 15:50:46 -0500</pubDate>
			<category>Science</category>
			<itunes:explicit>no</itunes:explicit>
			<itunes:duration>00:00:00</itunes:duration>
			<itunes:keywords>Multiple sclerosis, Interferon-beta, Glatiramer acetate, Natalizumab, Rituximab, Daclizumab, Alemtuzumab, Cladribine, Fingolimod, Teriflunomide, Laquinimod, BG00012</itunes:keywords>
		</item>
		<item>
			<title>Stephen L. Hauser, MD - Treatment Guidelines and Targeted Options for Multiple Sclerosis</title>
			<itunes:author>PVI, PeerView Institute for Medical Education</itunes:author>
			<description><![CDATA[In this activity, expert neurologists discuss the guidelines for an evidence-based use of broad-spectrum immunomodulatory therapies in multiple sclerosis and the rationales for integrating targeted therapies into the management of the disease.]]></description>
			<itunes:subtitle>Please be sure to view the accompanying (PDF) file for full CME/CE information.</itunes:subtitle>
			<itunes:summary>In this activity, expert neurologists discuss the guidelines for an evidence-based use of broad-spectrum immunomodulatory therapies in multiple sclerosis and the rationales for integrating targeted therapies into the management of the disease.</itunes:summary>
			<enclosure type="audio/mpeg" url="http://www.podtrac.com/pts/redirect.mp3?http://podcast.peerviewpress.com/neurology/PA03646FC2r341.mp3" length="29425579" />
			<link>http://podcast.peerviewpress.com/neurology/PA03646FC2r341.mp3</link>
			<guid>http://podcast.peerviewpress.com/neurology/PA03646FC2r341.mp3</guid>
			<pubDate>Thu, 25 Oct 2007 16:17:56 -0400</pubDate>
			<category>Science</category>
			<itunes:explicit>no</itunes:explicit>
			<itunes:duration>00:30:34</itunes:duration>
			<itunes:keywords>Alemtuzumab,
Antibody, antichimeric,
Antibody, monoclonal,
Antibody, neutralizing,
B cell,
CD20,
CD56,
Daclizumab,
Glatiramer acetate,
Idiopathic thrombocytopenic purpura (ITP),
Interferon beta,
Interleukin 2 (IL-2),
Mitoxantrone,
Multiple sclerosis</itunes:keywords>
		</item>
		<item>
			<title>CME/CE Information - Treatment Guidelines and Targeted Options for Multiple Sclerosis</title>
			<itunes:author>PVI, PeerView Institute for Medical Education</itunes:author>
			<description><![CDATA[Please view this PDF file for full CME/CE information.  You will need Adobe Acrobat reader software to access this file.]]></description>
			<itunes:subtitle>Please view this PDF file for full CME/CE information.  You will need Adobe Acrobat reader software to access this file.</itunes:subtitle>
			<itunes:summary>Please view this PDF file for full CME/CE information.  You will need Adobe Acrobat reader software to access this file.</itunes:summary>
			<enclosure type="application/pdf" url="http://podcast.peerviewpress.com/neurology/PA03646FC2CMEinfo.pdf" length="346256" />
			<link>http://podcast.peerviewpress.com/neurology/PA03646FC2CMEinfo.pdf</link>
			<guid>http://podcast.peerviewpress.com/neurology/PA03646FC2CMEinfo.pdf</guid>
			<pubDate>Thu, 25 Oct 2007 16:17:51 -0400</pubDate>
			<category>Science</category>
			<itunes:explicit>no</itunes:explicit>
			<itunes:duration>00:00:00</itunes:duration>
			<itunes:keywords>Alemtuzumab,
Antibody, antichimeric,
Antibody, monoclonal,
Antibody, neutralizing,
B cell,
CD20,
CD56,
Daclizumab,
Glatiramer acetate,
Idiopathic thrombocytopenic purpura (ITP),
Interferon beta,
Interleukin 2 (IL-2),
Mitoxantrone,
Multiple sclerosis</itunes:keywords>
		</item>
	</channel>
</rss>